Appareil pulmonaire CA209-73L A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) Paris
Appareil pulmonaire MARIPOSA (73841937NSC3003) A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy;Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with;EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer;MARIPOSA Paris NICOLAS GIRARD
Appareil pulmonaire TRIZELL rAd-IFN-MM-301 A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma Paris NICOLAS GIRARD
Appareil pulmonaire GeoMETry-III (CINC280A2301) A phase III, randomized, controlled, open-label, multicenter,;global study of capmatinib versus SoC docetaxel;chemotherapy in previously treated patients with EGFR wt,;ALK negative, locally advanced or metastatic (stage IIIB/IIIC;or IV) NSCLC harboring MET exon 14 skipping mutation;(METÀex14) Paris CATHERINE DANIEL
Appareil pulmonaire MS200647-0005 A Multicenter, Double Blind, Randomized,Controlled Study of M7824 with Concurrent Chemoradiation Followed by M7824 versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants with Unresectable Stage III Non-small Cell Lung Cancer· Protocol MS200647-0005 Paris CATHERINE DANIEL
Sein métastatique RH+ DESTINY-Breast06 (D9670C00001) A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator·s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06) Paris, Saint-Cloud JEAN-YVES PIERGA, ETIENNE BRAIN
Appareil pulmonaire AMG 20190009_25004 A Phase 3 Multicenter, Randomized, Open;Label, Active-controlled, Study of AMG 510;Versus Docetaxel for the Treatment of Previously;Treated Locally Advanced and Unresectable or;Metastatic NSCLC Subjects With Mutated;KRAS p.G12C Paris NICOLAS GIRARD
Appareil pulmonaire PAPILLON (61186372NSC3001 ) A Randomized, Open-label Phase 3 Study of Combination Amivantamab and;Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients;with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung;Cancer Paris NICOLAS GIRARD
Appareil pulmonaire TROPION-Lung01 (DS1062-A-U301) PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS;DOCETAXEL IN PREVIOUSLY TREATED ADVANCED;OR METASTATIC NON-SMALL CELL LUNG CANCER;WITHOUT ACTIONABLE GENOMIC ALTERATIONS;(TROPION-LUNG01) Paris NICOLAS GIRARD
Appareil pulmonaire AK112-301-HARMONi A randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment. Paris NICOLAS GIRARD